GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

GSK has posted a solid set of financial results in the first quarter of this year and said it is not too worried about the financial impact of potential pharma ... the five FDA product approvals ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

GlaxoSmithKline ( ($GSK) ) has shared an update. On May 7, 2025, GSK plc announced the purchase of 687,081 of its own ordinary shares at prices ...

Count North Carolina among the winners for enhanced trade alignment between the United States and the United Kingdom.

GlaxoSmithKline Pharmaceuticals Limited was erstwhile ... Also, they introduced the Animal health products. In the year 1971, the company built the Research & development laboratory at Thane.

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Bernstein analysts estimate that if a 20% tariff were applied to the cost of goods sold for U.S. sales, the impact on earnings would range from low- to high-single digits for major European drugmakers ...

I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call. [Operator Instructions] Also, today's conference is being recorded. And now, I would like to turn the ...

The deal includes two recently approved GSK products for metastatic melanoma ... The three way exchange of assets shows that these three major pharma players are happy to pursue divergent ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...